Our products reach 100 countriesClick here to learn more
Our activities incorporate all areas of the pharmaceutical value chainClick here to learn more
Innovation is one of the pillars of our strategy. We devoted EUR 48 million to research and development in the 2022/2023 financial year.Click here to learn more
The project "Egis eco-marathon", aimed at greening the company and its employees, received well-deserved recognition from specialists in the field of event marketing and was among the finalists in the category "Corporate Social Responsibility: Best ESG Project".
EMS (Environmental Management System) of EGIS-RUS successfully passed a certification audit for compliance with ISO 14001:2015 requirements. The audit was conducted by the International Organization for Standardization and Certification Bureau Veritas (Bureau Veritas Certification Rus JSC). Meeting the requirements of the ISO standards confirms the commitment of the management and employees to the highest requirements for climate protection and reduction of their environmental impact.
Egis launches in Russia a product with fixed-doses of atorvastatin and ezetimibe in one capsule for the treatment of hypercholesterolemia . Fixed-dose combination (FDC) developed by Egis will increase adherence in patients who take atorvastatin and ezetimibe separately, and a single dose per day should significantly simplify the drug therapy regimen.
Please report any adverse events